Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 27 Publications

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MUXGeY5kfGmxbjDBd5NigQ>? NYHIUJRIOjBizszN NG\5VJozPCCq NV\I[HVWcW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8> MX2yOVk1ODdzMh?=
MV-4-11 MXLBdI9xfG:|aYOgRZN{[Xl? MonHNk42KM7:TR?= M2C3flQ5KGh? M4DxbYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NIDCe4szPTFzMUW4Ny=>
THP-1 MUfBdI9xfG:|aYOgRZN{[Xl? NFHlbIozNjVizszN M3vxfFQ5KGh? NIHzOHFqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MX:yOVEyOTV6Mx?=
MOLM 13 M2e5U2Fxd3C2b4Ppd{BCe3OjeR?= M{PhS|IvPSEQvF2= MkDBOFghcA>? MWLpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= M1u3SFI2OTFzNUiz
KBM3/Bu2506 MlrWRZBweHSxc3nzJGF{e2G7 M{DmRVIvPSEQvF2= NGnMN4M1QCCq NHfvNIFqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NInTOoQzPTFzMUW4Ny=>
Nalm-6 NEj6TlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n5NGlEPTB;MUig{txO NH7MPWIzPTB4MUGwNS=>
Reh NVnxUFlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqzRVVFUUN3ME2zNEDPxE1? MUCyOVA3OTFyMR?=
U2937 M{G3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SzN2lEPTB;MU[g{txO NUm4XoVCOjVyNkGxNFE>
Mec-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7ITXUyUUN3MP-8olUxOCEQvF2= NI\Q[GEzPTB4MUGwNS=>
RPMI-8226 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrH[mhKSzVyPUWwNEDPxE1? M4TVWFI2ODZzMUCx
Molt-4 NXWwSWhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofoTWM2OD1zOECg{txO MVWyOVA3OTFyMR?=
Nalm-6-FluR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPXZmVKSzVyPUK1NEDPxE1? MlzwNlUxPjFzMEG=
Raji  M2\vPGZ2dmO2aX;uJGF{e2G7 M3P1dlPDqM7:TR?= M{j2cFI1NzR6L{eyJIg> NYjEb3RTcW6mdXPld{Bi[2O3bYXsZZRqd26|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=> M3X6UFI1QTRyNkm1
PBMC NETZe2RHfW6ldHnvckBCe3OjeR?= M33rUFUxNzFyMDFOwG0> MXWyOEBp MV\EUXNQ MVvpcohq[mm2czDTWGFVOSCyaH;zdIhwenmuYYTpc44> MUmyOFkyOTh5Mh?=
MDA-231 M1\VcWZ2dmO2aX;uJGF{e2G7 Ml3JNVAxKM7:TR?= NGr5fngzPCCq NETYUJlFVVOR M1r2U4Rm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?= MmjSNlQ6OTF6N{K=
624.38mel  MUTGeY5kfGmxbjDBd5NigQ>? MVW1NEDPxE1? MVqyOEBp NVH4UldwTE2VTx?= Mkmy[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w MnHFNlQ6OTF6N{K=
MDA-231 Mn65SpVv[3Srb36gRZN{[Xl? M4rN[VUxNTJyMDFOwG0> MYmyOEBp NV\MPZBYTE2VTx?= NYHU[ZB5cW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO= NWXvWG1WOjR7MUG4O|I>
624.38mel  MVvGeY5kfGmxbjDBd5NigQ>? NHjnepA2OC1{MECg{txO MljqNlQhcA>? NXrzVXFbTE2VTx?= MXnpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? MVKyOFkyOTh5Mh?=
HMECs NIHWRW5HfW6ldHnvckBCe3OjeR?= MlPpNVAxyqEQvF5CpC=> NH3oclY{PsLiaB?= MnzzbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> M1HGWFI1OjFzM{K3
HMECs  MXPGeY5kfGmxbjDBd5NigQ>? M1iwNFExOMLizszNxsA> NV76enVqOzcEoHi= Mnr6bY5pcWKrdIOgTWZP|rIEoH3l[IlifGWmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVOSCjbnSgV3RCXDNuIHL1eEBvd3Rib3[gV3RCXDJ? M{TZRlI1OjFzM{K3
BJAB NVTTZ3pKSXCxcITvd4l{KEG|c3H5 NFfOb|U2yqEQvF2= MmfvNlQhcA>? NH[2Z3hqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlLLNlQxPTdzNEe=
I-83 MV3BdI9xfG:|aYOgRZN{[Xl? MkTOOeKh|ryP M1zjV|I1KGh? NIDmRmlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHvEb5kzPDB3N{G0Oy=>
NALM6 NYnjR3l7SXCxcITvd4l{KEG|c3H5 MkO0OeKh|ryP NWHWcpNOOjRiaB?= NX3KUXRNcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NUHoUFRQOjRyNUexOFc>
DU-145 M2jjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDXflAxNTFyIN88[{9udA>? MmPXOFghcMLi MmrkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUjDR2FtOjN5M{S4NVU>
Nalm-6 MoDOSpVv[3Srb36gRZN{[Xl? NIPMNXQyOMLizszN NV7HZ5M1OS9{L{SgbC=> NEDYNo1qdmS3Y3XzJIF2fG:yaHHnfS=> NFzwN3czOzZ6MUKyNy=>
Reh M3j4c2Z2dmO2aX;uJGF{e2G7 M3;1W|ExyqEQvF2= MmrhNU8zNzRiaB?= NWfFUY5IcW6mdXPld{BifXSxcHjh[5k> NVqxVFN6OjN4OEGyNlM>
Nalm-6 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\NTWM2OCEkiMyxNQKBkc7:TR?= NG\lPVgzOzZ6MUKyNy=>
Reh MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml34TWM2OCEkiMyxNQKBkc7:TR?= NEHiOWgzOzZ6MUKyNy=>
HEC1A MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD2OHYyODBvNUCwJO69VQ>? NX[4Z2liOjRiaB?= Ml;RbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4f5XFI{PTl3Nkm3
AN3CA MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf3UXEyODBvNUCwJO69VQ>? MXWyOEBp NXfERWQycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmCwNlM2QTV4OUe=
HEC50B NITRVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq0Z3RvOTByLUWwNEDPxE1? NWjJfYU{OjRiaB?= NYexN21KcW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? M4HRVFI{PTl3Nkm3
HEC1A MULBdI9xfG:|aYOgRZN{[Xl? MWKyNE8yODBizszN M2\m[FI1KGh? MXzpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmjQNlM2QTV4OUe=
AN3CA M2nOR2Fxd3C2b4Ppd{BCe3OjeR?= MWeyNE8yODBizszN MXKyOEBp NYjvWpFmcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3T4V|I{PTl3Nkm3
HEC50B MXPBdI9xfG:|aYOgRZN{[Xl? M1jYOVIxNzFyMDFOwG0> NEjrUGgzPCCq NVLOU5NucW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M37KTlI{PTl3Nkm3
EHEB NV7sNYJZSXCxcITvd4l{KEG|c3H5 MmDLOFAh|ryP NVv3Wo5tOjRiaB?= M3zZNIlv\HWlZYOgZZBweHSxc3nz M3T6N|I{PDl5MEe1
A549 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF3LkhCtVIvQCEEtV2= M2Hu[|I{Ozd5MUmy
A549 GAPDH-deficient M3POc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXiSJNKSzVyPUG4MlXDuTJwMzFCuW0> NXm5WHp{OjN|N{exPVI>
CLL  NVvBfG9pSXCxcITvd4l{KEG|c3H5 MYWxNEDPxE4EoB?= NILqbGYzPC17NjDo MYnpcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo MYqyNlIxPzZ6Nh?=
MEC1 MWfBdI9xfG:|aYOgRZN{[Xl? MXqxNFDDqM7:TR?= MWC3NkBp Mk\PbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MkXsNlIyOzJ7N{O=
U937  MXTBdI9xfG:|aYOgRZN{[Xl? MX2wMlgh|ryP M1fhWlQuPDhiaB?= NV;iW41LcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MkLZNlIxPzR5MEC=
U937  M4jt[2Fxd3C2b4Ppd{BCe3OjeR?= NIOySlYyKM7:TR?= NGLmPIg6PiCq NV3qTYc5cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MYqyNlAzOzV{Mx?=
Daudi NHvxOIJCeG:ydH;zbZMhSXO|YYm= NUfJOnBDOjBizszN MmfJPVYhcA>? NWLWVVI1cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> Mn;oNlIxOjN3MkO=
J45.01 M{OyTGFxd3C2b4Ppd{BCe3OjeR?= MYSxJO69VQ>? M{G4Vlk3KGh? Mn\ubY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MlTaNlIxOjN3MkO=
RPMI 8226 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;CbZJvUUN3ME2yOU46yqEEsdMgN{44KM7:TR?= NIDQU2gzOTl2OEK2OC=>
CEM NHrqXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qzN2lEPTB;Mj60xsDDucLiMD60JO69VQ>? NIfiN3kzOTl2OEK2OC=>
Raji MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXyO4Z7UUN3ME2wMlQ4yqEEsdMgNE4xPCEQvF2= M16xUlIyQTR6Mk[0
U937 NXTrW3hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTBcI9CUUN3ME2wMlI1yqEEsdMgNE4xPCEQvF2= MlXtNlE6PDh{NkS=
K562 NY[4RY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmwW2lIUUN3ME2wMlQ1yqEEsdMgNE4xPSEQvF2= NILpN3YzOTl2OEK2OC=>
NALM-6 M3zDUWFxd3C2b4Ppd{BCe3OjeR?= MlHENVAh|ryPwrC= MV:yOEBp NH3kRplqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 M4LZTVIyPjl7M{iz
JMV-3 MXnBdI9xfG:|aYOgRZN{[Xl? Ml;JNVAh|ryPwrC= M4fuflI1KGh? NEftdYZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 M3rZdlIyPjl7M{iz
EHEB NGf4ZWZHfW6ldHnvckBCe3OjeR?= MUO1MVUxKM7:TR?= NIW3cJUzPCCq M{K1cIRm[3KnYYPld{BxOjFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 MlHiNlEyPjh|OUG=
JVM-2  MlzKSpVv[3Srb36gRZN{[Xl? MWWzNEDPxE1? MV6yOEBp NVnpfGxH\GWlcnXhd4V{KHB{MTDlfJBz\XO|aX;u MV6yNVE3QDN7MR?=
KBM3/Bu2506 NEPUPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjsToZUUUN{ME2wMlY4KML3TR?= MY[yNFk{OzVyOR?=
KBM3/Bu2506 NEfnXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYewMlYh|ryP MUSyOEBp NVHlTmhvcW6lcnXhd4V{KHSqZTDj[YxtKG[{YXP0bY9vKGmwIGOtdIhie2V? NIDUfXozODl|M{WwPS=>
MDA-MB-231 NVPtcmhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRwMDFOwG0> MX6yNFQ1PzN7MB?=
MCF-7 NX;ibVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XoPWlEPTB;MUWuNEDPxE1? MV6yNFQ1PzN7MB?=
HLE-B3  NGnvOINHfW6ldHnvckBCe3OjeR?= M3:4dFI2KM7:TR?= NVXOOY5JPDhiaB?= M1PWeYJtd2OtczDJSm4u|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44> NGSxb28zODR|NUG1PC=>
K562 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH4S5Q4OiCq MoDGTWM2OD1|LkOgcm0> M4T0WVIxOzB5MUm4
BW-225 NX3meVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO2T|MxUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> NXjXW4R{OTh4NkGzPFA>
OH-65 M1jr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|IxRTFwM{egx7cyOOLKkklCpO69VcLi NXi3UI5FOTh4NkGzPFA>
GR-145 NU\VRmppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrIdVRKSzJyPUKuO|Qhy5diMUFijLI5KCEQvF5CpC=> NH;SWY4yQDZ4MUO4NC=>
A549 NH\sR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|IxRTVwNEigx7chOTEkiKK4JO69VcLi NUO0T|dpOTh4NkGzPFA>
CaSki  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\TTGlEOjB;MT6zO{DEnyBzMPMIllch|ryPwrC= MYixPFY3OTN6MB?=
ZMK-1 NWfIVXZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrEVHRiUUN{ME2xMlM4KMPZIEGw5qiTPiEQvF5CpC=> MnrrNVg3PjF|OEC=
SKW6.4 NGXwdFlCeG:ydH;zbZMhSXO|YYm= NIfaWJQxNjBzLUGwJO69VQ>? NUjqdJQ5OjRxNEigbC=> M2TqXYlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NYXXeVVTOThyOUKzOFA>
RPMI 8226 NV3NZnFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELIUXUzPCCq M1LuWmlEPTB;MT61OOKh|ryP NV:4dmF5OTd7N{[xPFY>
MM.1S NFTG[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXXdW41QCCq NXjRSXIzUUN3ME2xN{41QMLizszN M{HVb|E4QTd4MUi2
MM.1R M4\YW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7jTZQ1QCCq NIXrNHBKSzVyPUOzMlc6KM7:TR?= MXexO|k4PjF6Nh?=
U937 M2nKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\CUWlEPTB;MzyyNFAhyrFiNU[wJI5O NFHlb4YyPTl|MEO2NS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
procaspase-9 / procaspase-3; 

PubMed: 27223263     


Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control.

p-p53 / p53; 

PubMed: 27223263     


(A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒

STAT1; 

PubMed: 26677135     


Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.

27223263 26677135
Immunofluorescence
α-SMA / Vimentin; 

PubMed: 28322315     


FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).

28322315
Growth inhibition assay
Cell viability ; 

PubMed: 24956101     


CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.

24956101
In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03710421 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma City of Hope Medical Center|National Cancer Institute (NCI) June 10 2019 Phase 1
NCT03856216 Not yet recruiting Acute Lymphoblastic Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|B Acute Lymphoblastic Leukemia|CD22 Positive|Lymphocytic Neoplasm|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) June 30 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products0

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID